Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea

被引:0
|
作者
Jung Wan Park
Hyungmin Lee
Jung Wook Kim
Bongyoung Kim
机构
[1] Korea Centers for Disease Control and Prevention,Department of Healthcare
[2] Asan Medical Center,Associated Infection Control
[3] University of Ulsan College of Medicine,Department of Infectious Diseases
[4] Center for Infectious Diseases Research,Division of Antimicrobial Resistance
[5] Korea National Institute of Health,Department of Internal Medicine
[6] Korea Centers for Disease Control and Prevention,undefined
[7] Hanyang University College of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study was to describe the characteristics of infections with Staphylococcus aureus with reduced vancomycin susceptibility (SARVS) including vancomycin-intermediate S. aureus (VISA) in South Korea, using data from the national sentinel surveillance system during 2014–2016. A total of 66 patients infected or colonized with SA-RVS were reported using the sentinel surveillance system. Among them, VISA was confirmed in 14 isolates (21.2%) and no vancomycin-resistant S. aureus (VRSA) was detected. Most of patients had any kind of indwelling devices (81.8%, 54/66) and underwent surgical procedures in the previous 6 months (84.8%, 56/66). Patients who admitted to an intensive care unit (ICU) in the previous 3 months were 68.2% (45/66). Furthermore, patients who used vancomycin or had MRSA in the previous 1 month were 54.5% (36/66) and 59.1% (39/66), respectively. Upon review of the medical records, 54.5% (36/66) of patients were classified as having SA-RVSassociated infection and 30-day mortality was 19.4% (7/36). Our findings revealed that there was no VRSA in South Korea. SA-RVS including VISA existed particularly in patients who had indwelling devices, history of surgical procedure, and history of ICU admission.
引用
收藏
相关论文
共 50 条
  • [1] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Park, Jung Wan
    Lee, Hyungmin
    Kim, Jung Wook
    Kim, Bongyoung
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] Vancomycin-intermediate Staphylococcus aureus in Korea
    Kim, MN
    Pai, CH
    Woo, JH
    Ryu, JS
    Hiramatsu, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3879 - 3881
  • [3] Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid
    Balkhair, Abdullah
    Al Muharrmi, Zakariya
    Darwish, Laila
    Farhan, Hatem
    Sallam, Mansour
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E227 - E229
  • [4] Heteroresistance in Vancomycin-Intermediate Staphylococcus aureus (VISA), susceptible or resistant?
    Labarca, Jaime
    REVISTA CHILENA DE INFECTOLOGIA, 2015, 32 (05): : 497 - 498
  • [5] Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
    Cui, LZ
    Tominaga, E
    Neoh, HM
    Hiramatsu, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 1079 - 1082
  • [6] Vancomycin-intermediate resistance in Staphylococcus aureus
    Hiramatsu, Keiichi
    Kayayama, Yuki
    Matsuo, Miki
    Aiba, Yoshifumi
    Saito, Michie
    Hishinuma, Tomomi
    Iwamoto, Akira
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (04) : 213 - 224
  • [7] Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA)
    Howden, BP
    INTERNAL MEDICINE JOURNAL, 2005, 35 : S136 - S140
  • [8] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    Fong, R. K. C.
    Low, J.
    Koh, T. H.
    Kurup, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) : 983 - 987
  • [9] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    R. K. C. Fong
    J. Low
    T. H. Koh
    A. Kurup
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [10] Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
    Su, Michelle
    Davis, Michelle H.
    Peterson, Jessica
    Solis-Lemus, Claudia
    Satola, Sarah W.
    Read, Timothy D.
    PEERJ, 2021, 9